Additional capital for AC BioScience

AC BioScience is a biotech company pioneering the development of novel therapies in immuno-oncology and tumour vascular normalisation. Based on molecular profiling, the startup develops personalized molecular therapies designed to optimize efficiency or bolster the therapeutic benefit for particular groups of patients battling cancer. The company does not conduct R&D discovery, but it develops only those molecules with a previous history of extensive and successful pre-clinical research.  

Currently, the company's pipeline comprises three candidates;  sphingosine-1-phosphate (S.1.p) metabolism modulators used as tumour vascular normalizers to improve the efficacy of chemo- and radiotherapy in the treatment of solid tumours. The A Beta-carboline derivative (ACB1801) aims to revert the tumour phenotype and thereby enhance the efficacy of checkpoint-inhibitor immune therapy, and the cationic amphipathic peptide (CAP6) is a patented antitumor therapy that belongs to a new generation of cancer drugs with limited side effects and generally greater efficacy. Two proprietary cancer molecules have already successfully passed the discovery stage and pre-clinical testing.

Today, the startup announced the closing of a second seed round, raising an additional one million Swiss Franks which brings the total amount in the seed round to CHF 2 million. This bridge funding precedes a planned Series A round in late 2020 to fund the planned clinical trials in 2021.  

AC BioScience is one of the startups presenting at the 9th International Cancer Cluster Showcase - BIO Digital 2020 on 8 June 2020.

(Press release/ran)